Grifols S.A. (GRF) - Net Assets

Latest as of June 2025: €7.60 Billion EUR ≈ $8.88 Billion USD

Based on the latest financial reports, Grifols S.A. (GRF) has net assets worth €7.60 Billion EUR (≈ $8.88 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€19.77 Billion ≈ $23.11 Billion USD) and total liabilities (€12.17 Billion ≈ $14.23 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GRF PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets €7.60 Billion
% of Total Assets 38.44%
Annual Growth Rate 30.35%
5-Year Change 28.08%
10-Year Change 160.71%
Growth Volatility 123.39

Grifols S.A. - Net Assets Trend (2005–2024)

This chart illustrates how Grifols S.A.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see GRF market cap.

Annual Net Assets for Grifols S.A. (2005–2024)

The table below shows the annual net assets of Grifols S.A. from 2005 to 2024. Also explore GRF net asset momentum to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2024-12-31 €8.61 Billion
≈ $10.06 Billion		 +7.96%
2023-12-31 €7.97 Billion
≈ $9.32 Billion		 -5.74%
2022-12-31 €8.46 Billion
≈ $9.89 Billion		 +3.81%
2021-12-31 €8.15 Billion
≈ $9.52 Billion		 +21.23%
2020-12-31 €6.72 Billion
≈ $7.86 Billion		 -1.84%
2019-12-31 €6.85 Billion
≈ $8.00 Billion		 +45.76%
2018-12-31 €4.70 Billion
≈ $5.49 Billion		 +29.24%
2017-12-31 €3.63 Billion
≈ $4.25 Billion		 -2.52%
2016-12-31 €3.73 Billion
≈ $4.36 Billion		 +12.92%
2015-12-31 €3.30 Billion
≈ $3.86 Billion		 +23.98%
2014-12-31 €2.66 Billion
≈ $3.11 Billion		 +26.37%
2013-12-31 €2.11 Billion
≈ $2.46 Billion		 +12.04%
2012-12-31 €1.88 Billion
≈ $2.20 Billion		 +12.96%
2011-12-31 €1.66 Billion
≈ $1.95 Billion		 +135.37%
2010-12-31 €707.39 Million
≈ $827.01 Million		 +22.27%
2009-12-31 €578.53 Million
≈ $676.36 Million		 +20.21%
2008-12-31 €481.28 Million
≈ $562.67 Million		 +25.28%
2007-12-31 €384.17 Million
≈ $449.13 Million		 +4.29%
2006-12-31 €368.35 Million
≈ $430.64 Million		 +558.39%
2005-12-31 €55.95 Million
≈ $65.41 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Grifols S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 704.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings €205.68 Million 3.50%
Common Stock €119.60 Million 2.03%
Other Comprehensive Income €4.78 Billion 81.28%
Other Components €776.28 Million 13.19%
Total Equity €5.88 Billion 100.00%

Grifols S.A. Competitors by Market Cap

The table below lists competitors of Grifols S.A. ranked by their market capitalization.

Company Market Cap
Icahn Enterprises LP
NASDAQ:IEP
 $4.85 Billion
Hangcha Group Co Ltd
SHG:603298
 $4.85 Billion
Boc International China Co Ltd
SHG:601696
 $4.85 Billion
Beijing Tongrentang Co Ltd
SHG:600085
 $4.85 Billion
AUTO TRADER ADR 1/4 LS-01
F:2UA0
 $4.85 Billion
Spire Inc
NYSE:SR
 $4.85 Billion
Shandong Himile Mechanical Science & Technology Co Ltd
SHE:002595
 $4.84 Billion
BRF S.A
F:P5Y
 $4.84 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Grifols S.A.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 5,827,166,000 to 5,883,727,000, a change of 56,561,000 (1.0%).
  • Net income of 156,920,000 contributed positively to equity growth.
  • Dividend payments of 962,000 reduced retained earnings.
  • Other comprehensive income decreased equity by 108,105,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income €156.92 Million +2.67%
Dividends Paid €962.00K -0.02%
Other Comprehensive Income €-108.11 Million -1.84%
Other Changes €8.71 Million +0.15%
Total Change €- 0.97%

Book Value vs Market Value Analysis

This analysis compares Grifols S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.13x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 74.07x to 1.13x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-12-31 €0.13 €9.82 x
2006-12-31 €0.86 €9.82 x
2007-12-31 €0.78 €9.82 x
2008-12-31 €0.99 €9.82 x
2009-12-31 €1.17 €9.82 x
2010-12-31 €1.57 €9.82 x
2011-12-31 €2.52 €9.82 x
2012-12-31 €2.74 €9.82 x
2013-12-31 €3.09 €9.82 x
2014-12-31 €3.88 €9.82 x
2015-12-31 €4.81 €9.82 x
2016-12-31 €5.44 €9.82 x
2017-12-31 €5.30 €9.82 x
2018-12-31 €6.17 €9.82 x
2019-12-31 €7.04 €9.82 x
2020-12-31 €7.46 €9.82 x
2021-12-31 €8.98 €9.82 x
2022-12-31 €9.04 €9.82 x
2023-12-31 €8.58 €9.82 x
2024-12-31 €8.65 €9.82 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Grifols S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 2.67%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 2.18%
  • • Asset Turnover: 0.34x
  • • Equity Multiplier: 3.64x
  • Recent ROE (2.67%) is below the historical average (14.99%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 45.78% 4.87% 0.64x 14.72x €19.97 Million
2006 12.34% 7.00% 0.71x 2.48x €8.60 Million
2007 22.91% 12.48% 0.75x 2.45x €49.46 Million
2008 25.36% 14.95% 0.69x 2.46x €73.73 Million
2009 26.13% 16.20% 0.55x 2.93x €91.33 Million
2010 16.67% 11.66% 0.52x 2.73x €46.21 Million
2011 3.03% 2.80% 0.31x 3.49x €-115.94 Million
2012 13.68% 9.79% 0.47x 3.00x €69.01 Million
2013 16.44% 12.60% 0.47x 2.78x €135.42 Million
2014 17.69% 14.01% 0.40x 3.18x €204.44 Million
2015 16.14% 13.52% 0.41x 2.91x €202.52 Million
2016 14.66% 13.47% 0.40x 2.72x €173.31 Million
2017 18.26% 15.35% 0.40x 3.01x €299.79 Million
2018 14.12% 13.30% 0.36x 2.95x €174.09 Million
2019 12.96% 12.26% 0.33x 3.22x €142.93 Million
2020 12.11% 11.58% 0.35x 2.99x €107.71 Million
2021 4.35% 5.38% 0.26x 3.15x €-344.34 Million
2022 3.40% 3.43% 0.28x 3.51x €-404.71 Million
2023 1.02% 0.90% 0.31x 3.68x €-523.40 Million
2024 2.67% 2.18% 0.34x 3.64x €-431.45 Million

Industry Comparison

This section compares Grifols S.A.'s net assets metrics with peer companies in the Drug Manufacturers - General industry.

No peer company data available for comparison.

About Grifols S.A.

MC:GRF Spain Drug Manufacturers - General
Market Cap
$4.85 Billion
€4.15 Billion EUR
Market Cap Rank
#3680 Global
#30 in Spain
Share Price
€9.82
Change (1 day)
-0.79%
52-Week Range
€8.67 - €12.61
All Time High
€33.56
Categories
Companies in Spain Drug Manufacturers - General
About

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more